Stockscreener 앱 받기
8.25
0.60%
-0.05
시간 외 거래:
8.25
전일 마감가:
$8.30
열려 있는:
$8.15
하루 거래량:
875.84K
Relative Volume:
0.62
시가총액:
$815.50M
수익:
$84.28M
순이익/손실:
$-171.30M
주가수익비율:
-4.7487
EPS:
-1.7373
순현금흐름:
$-171.21M
1주 성능:
+0.12%
1개월 성능:
-12.61%
6개월 성능:
-15.73%
1년 성능:
-29.18%
1일 변동 폭
$8.00
$8.405
1주일 범위
$8.00
$9.106
52주 변동 폭
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
명칭
Ars Pharmaceuticals Inc
전화
858-771-9307
주소
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
8.25 | 820.44M | 84.28M | -171.30M | -171.21M | -1.7373 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-04 | 재개 | Roth Capital | Buy |
| 2025-09-04 | 개시 | Roth Capital | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-10 | 개시 | Oppenheimer | Outperform |
| 2024-08-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | 재확인 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | Raymond James | Outperform |
| 2024-03-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 개시 | William Blair | Outperform |
| 2022-12-13 | 개시 | SVB Leerink | Outperform |
모두보기
Ars Pharmaceuticals Inc 주식(SPRY)의 최신 뉴스
Will ARS Pharmaceuticals Inc stock recover after earnings2026 Buyback Activity & Real-Time Buy Zone Alerts - baoquankhu1.vn
Update Report: Can ARS Pharmaceuticals Inc sustain earnings growthBond Market & Community Verified Trade Signals - baoquankhu1.vn
Lexicon Pharmaceuticals (LXRX) 2025 10-K: pipeline updates, collaborations - Stock Titan
Bamco Inc. NY Boosts Stake in ARS Pharmaceuticals - National Today
Bamco Inc. NY Buys 1,228,532 Shares of ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Casdin Capital LLC Purchases New Stake in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
SPRY SEC FilingsARS Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
Breakout Move: Can ARS Pharmaceuticals Inc stock outperform in a bear market2026 Update & Real-Time Price Movement Reports - baoquankhu1.vn
Institution Moves: What analysts say about ARS Pharmaceuticals Inc stock2026 Major Catalysts & Technical Pattern Recognition Alerts - baoquankhu1.vn
Guidance Update: Is ARS Pharmaceuticals Inc a top pick in the sectorProfit Target & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
ARS Pharmaceuticals, Inc. (SPRY) reports Q4 loss, beats revenue estimates - MSN
[ARS] CUMBERLAND PHARMACEUTICALS INC SEC Filing - Stock Titan
How (SPRY) Movements Inform Risk Allocation Models - Stock Traders Daily
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY) - Seeking Alpha
SPRY: Expanding neffy access, advancing urticaria trials, and strong global uptake drive future growth - TradingView
SPRY: Expanding neffy access and advancing urticaria trials drive growth, with strong global uptake - TradingView
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY), BillionToOne, Inc. Class A (BLLN) and Praxis Precision Medicines (PRAX) - The Globe and Mail
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates - MSN
Leerink raises ARS Pharmaceuticals stock price target on sales expansion - Investing.com Australia
Leerink raises ARS Pharmaceuticals stock price target on sales expansion By Investing.com - Investing.com Canada
Earnings call transcript: ARS Pharmaceuticals beats Q4 2025 forecasts, stock rises - Investing.com India
Earnings call transcript: ARS Pharmaceuticals beats Q4 2025 forecasts, stock rises By Investing.com - Investing.com South Africa
ARS Pharmaceuticals (SPRY) Q3 Loss Of US$51 Million Tests Bullish Profitability Narrative - Sahm
ARS Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
ARS Pharmaceuticals Announces Strong 2025 Financial Results and neffy® Commercial Launch Progress, Highlights Global Approvals and Market Expansion - Minichart
ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earnings Call Highlights: Strong Market Entry and ... By GuruFocus - Investing.com Canada
ARS Pharmaceuticals (SPRY) Posts Q4 Loss of $0.42/Share as Revenue Jumps 332% YoY to $28.1M - AlphaStreet
ARS Pharmaceuticals outlines sales force expansion and digital strategy for neffy growth while maintaining SG&A in 2026 - MSN
SPRY: neffy’s needle-free nasal spray is transforming emergency allergy care and driving rapid market growth - TradingView
ARS Pharmaceuticals, Inc. 2025 Annual Report: Business Overview, Risk Factors, and Strategy for Neffy Commercialization 49 - Minichart
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® Commercialization - Investing News Network
ARS Pharmaceuticals earnings beat by $0.01, revenue topped estimates - Investing.com Canada
ARS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ARS Pharmaceuticals, Inc. (SPRY) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
ARS Pharmaceuticals (NASDAQ:SPRY) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat
ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q4 Revenue $28.1M - marketscreener.com
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 Net Loss $0.42 a Share, vs. FactSet Est of $0.39 Loss - marketscreener.com
ARS Pharmaceuticals Reports 2025 Results and neffy Growth - TipRanks
ARS Pharmaceuticals Inc (NASDAQ: SPRY) announces that the regulatory approval timeline for its nasal spray epinephrine product Neffy in Canada has been clarified. - Bitget
ARS Pharmaceuticals 2025 10-K: $84.3M Revenue, $(1.74) EPS - TradingView
ARS Pharmaceuticals Q4 revenue beats expectations on strong neffy sales - TradingView
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization - ChartMill
Aug Levels: Will ARS Pharmaceuticals Inc. stock recover after earningsEarnings Beat & Free Reliable Trade Execution Plans - baoquankhu1.vn
Exploring ARS Pharmaceuticals's Earnings Expectations - Benzinga
What To Expect From ARS Pharmaceuticals Inc (SPRY) Q4 2025 Earni - GuruFocus
ARS Pharmaceuticals (SPRY) Expected to Announce Earnings on Monday - MarketBeat
ARS Pharmaceuticals, Inc. (SPRY): Analyst Consensus Sees 214% Upside Potential - DirectorsTalk Interviews
Raymond James reiterates Strong Buy on ARS Pharmaceuticals stock By Investing.com - Investing.com South Africa
Ars Pharmaceuticals Inc (SPRY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):